Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase III AIR-CF1 (CP-AI-007) study of aztreonam lysine for inhalation for the treatment of people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) met its primary efficacy endpoint of change at Day 28 from baseline in respiratory symptoms, as assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a patient-reported outcome (PRO) tool used to measure health-related quality of life for people with CF. Data from the 164-patient, double-blinded, randomized study demonstrated a significant improvement in the CFQ-R, with a treatment difference in mean change from baseline of 9.7 points in the respiratory domain (on a scale of 100) compared to placebo (p less than 0.001) following a 28-day treatment course with 75 mg aztreonam lysine for inhalation or volume-matched placebo administered three times daily by the PARI eFlow(R) Electronic Nebulizer. Aztreonam lysine-treated patients also experienced significant improvements at Day 28 in respiratory function, as measured by relative improvement of FEV1, with a treatment difference in mean change from baseline of 10.3 percent versus placebo (p less than 0.001). Full study results will be submitted for presentation at an upcoming scientific meeting.

The most common treatment-emergent adverse events in this study were cough, productive cough, nasal congestion, sore throat and dyspnea (shortness of breath). The incidences of these events were not significantly different between the placebo and the aztreonam lysine groups.

"The FDA, Cystic Fibrosis Foundation and medical community have identified PROs as important endpoints in clinical trials for CF and a variety of other diseases," said A. Bruce Montgomery, MD, Senior Vice President, Head of Respiratory Therapeutics, Gilead Sciences. "AIR-CF1 is the first Phase II
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... and RALEIGH, N.C. , Dec. ... LLC (CTMC), and Integrated Clinical Trial Services, LLC ... retention for clinical trials announce that they have ... Marketing Services (i-CTMS). i-CTMS will provide a broad ... pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... ANF Group, Inc ., a South Florida based ... 170,000-square-foot Joe DiMaggio Children,s Hospital – the first free ... (Photo: http://photos.prnewswire.com/prnh/20110614/FL18288 ) The hospital,s ... designed to earn Gold Leadership in Energy and Environment ...
... June 14, 2011 CVS/pharmacy provides ... at more than 7,200 convenient locations nationwide. Shoppers have come ... larger-than-ever selection of gifts, goods and everyday needs. From popular ... the hottest gear and thoughtful keepsakes perfect for every dad, ...
Cached Medicine Technology:ANF Group, Inc. Completes New Joe DiMaggio Children's Hospital 2Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 2Find the Best in Gadgets, Grilling and Grooming in Just One Stop This Father's Day at CVS/pharmacy 3
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress wholesaler and retailer, ... for 2015. Great discounts are now offered on all ... get a discount, up to 80% off, when they ... 30, 2015. , VogueQueen.com has recently released its new ... promotion. Many customers worldwide like VogueQueen’s special designs which ...
(Date:12/20/2014)... the distinguished wedding dress manufacturer and retailer, has just ... has recently updated its official blog with the latest ... Angeldress Blog has recommended some new designs and ... in offering a huge selection of elegant products and ... are very carefully selected based on the design and ...
(Date:12/20/2014)... CA (PRWEB) December 20, 2014 Atore, ... Innovation company just launched first birthday focused portal on ... “MERRY BIRTHDAY MESSAGE” launched in both US and Japan. ... BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY ... everyone’s birthday around the world. , Features, Choose from ...
(Date:12/20/2014)... 20, 2014 Recently, AngelWeddingDress.com has introduced ... ”) for the coming Christmas. In the promotion, all ... off. , “We have something special for the women ... holiday season. Moreover, our new collections of 2015 dresses ... offered now at greatly discounted prices. Visit our website ...
(Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
Breaking Medicine News(10 mins):Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... do not achieve statistical significance, - GPC Biotech schedules conference call ... ... ET/13:30 CET, BOULDER, Colo., MARTINSRIED, Germany, MUNICH, Germany and PRINCETON,N.J., ... AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq:,GPCB) today announced topline ...
... Survival Results Do Not Achieve Statistical Significance, ... SPPI ) licensee, GPC Biotech, today,announced that ... the,treatment of hormone-refractory prostate cancer did not meet ... that the overall survival data for,satraplatin did not ...
... Oct. 30 Barr,Pharmaceuticals, Inc. (NYSE: BRL ... has received tentative approval from the U.S. Food ... Boehringer Ingelheim,Pharmaceuticals, Inc.,s Mirapex(R) (Pramipexole Dihydrochloride) Tablets,0.125mg, 0.25mg, ... it is the,first to file an Abbreviated New ...
... at the Albert Einstein College of Medicine of Yeshiva ... can be successfully treated by targeting the viruses ... 31 issue of PloS One, also raise the possibility ... turn cancerous. , The Einstein researchers used a technique ...
... 79% Growth Over Prior Year Quarter; ... 2008 Guidance, COEUR D,ALENE, Idaho, Oct. 30 ... provider of radiology,solutions to radiology groups across the United ... September 30, 2007. Revenue,grew 79% year-over-year to a record ...
... and OMX Nordic Exchange: EPCT) today announced that Jack ... BioFin Rodman & Renshaw,9th Annual Healthcare Conference on November ... York Palace Hotel in New York. Mr. Talley will ... The presentation will be available live via webcast ...
Cached Medicine News:Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 2Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 3Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 4Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 2Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 2Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 4Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 2Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
FF 450plus IRu Fundus camera with Visupac / System 431. Digital results in all capture modes and unlimited Visupac software....
The most advanced retinal cameras for fluorescein, color and ICG angiography with full digital imaging capability....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: